» Articles » PMID: 33276479

TNF-α Priming Elicits Robust Immunomodulatory Potential of Human Tonsil-Derived Mesenchymal Stem Cells to Alleviate Murine Colitis

Overview
Journal Biomedicines
Date 2020 Dec 5
PMID 33276479
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Mesenchymal stem cells (MSCs) have been spotlighted in the field of cell therapies as a promising tool for the treatment of intractable inflammatory diseases. However, their therapeutic potency still shows a gap between preclinical and clinical settings, and distinctive characteristics of specific tissue-derived MSCs and definitive ways to maximize their beneficial functions have not been fully elucidated yet. We previously identified the unique MSCs population from human palatine tonsil (TMSCs) and revealed their superior properties in proliferation and ROS regulation. Based on these findings, we explored further characteristics of TMSCs particularly focused on immunomodulatory function. We found the merit of TMSCs as a therapeutic agent that retains favorable MSCs properties until relatively late passages and revealed that pre-treatment of TNF-α can enhance the immunomodulatory abilities of TMSCs through the upregulation of the PTGS2/PGE axis. TMSCs primed with TNF-α effectively restrained the proliferation and differentiation of T lymphocytes and macrophages in vitro, and more interestingly, these TNF-α-licensed TMSCs exhibited significant prophylactic and therapeutic efficacy in a murine model of autoimmune-mediated acute colitis via clinical and histopathological assessment compared to unprimed naïve TMSCs. These findings provide novel insight into the optimization and standardization of MSCs-based anti-inflammatory therapies, especially targeting inflammatory bowel disease (IBD).

Citing Articles

Machine learning reveals the rules governing the efficacy of mesenchymal stromal cells in septic preclinical models.

Gakhar D, Joshi H, Makkar D, Taneja N, Arora A, Rakha A Stem Cell Res Ther. 2024; 15(1):289.

PMID: 39256841 PMC: 11389403. DOI: 10.1186/s13287-024-03873-3.


Immunomodulatory potential of cytokine-licensed human bone marrow-derived mesenchymal stromal cells correlates with potency marker expression profile.

Wang J, Zhou Y, Donohoe E, Canning A, Moosavizadeh S, Ryan A Stem Cells. 2024; 42(12):1040-1054.

PMID: 39208292 PMC: 11630899. DOI: 10.1093/stmcls/sxae053.


Therapeutic Extracellular Vesicles from Tonsil-Derived Mesenchymal Stem Cells for the Treatment of Retinal Degenerative Disease.

Choi S, Seo S, Hong H, Yoon S, Kim M, Moon S Tissue Eng Regen Med. 2023; 20(6):951-964.

PMID: 37440108 PMC: 10519919. DOI: 10.1007/s13770-023-00555-8.


Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and Challenges.

Tian C, Zhang Y, Yang M, Xu H, Zhu M, Yao J J Inflamm Res. 2023; 16:2089-2119.

PMID: 37215379 PMC: 10199681. DOI: 10.2147/JIR.S400447.


Therapeutic potential of mesenchymal stem/stromal cells (MSCs)-based cell therapy for inflammatory bowel diseases (IBD) therapy.

Saadh M, Mikhailova M, Rasoolzadegan S, Falaki M, Akhavanfar R, Gonzales J Eur J Med Res. 2023; 28(1):47.

PMID: 36707899 PMC: 9881387. DOI: 10.1186/s40001-023-01008-7.


References
1.
Kim J, Park M, Kim Y, Ryu K, Lee K, Cho K . Tonsil-derived mesenchymal stem cells (T-MSCs) prevent Th17-mediated autoimmune response via regulation of the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) pathway. J Tissue Eng Regen Med. 2017; 12(2):e1022-e1033. DOI: 10.1002/term.2423. View

2.
Galipeau J . Reply: "Function of Cryopreserved Mesenchymal Stromal Cells With and Without Interferon-γ Prelicensing Is Context Dependent". Stem Cells. 2016; 35(5):1440-1441. DOI: 10.1002/stem.2526. View

3.
Park G, Song J, Park H, Shin S, Jang J, Lee J . Role of Fibroblast Growth Factor-5 on the Proliferation of Human Tonsil-Derived Mesenchymal Stem Cells. Stem Cells Dev. 2016; 25(15):1149-60. DOI: 10.1089/scd.2016.0061. View

4.
Lee K, Hui J, Song I, Ardany L, Lee E . Injectable mesenchymal stem cell therapy for large cartilage defects--a porcine model. Stem Cells. 2007; 25(11):2964-71. DOI: 10.1634/stemcells.2006-0311. View

5.
Ryan J, Barry F, Murphy J, Mahon B . Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol. 2007; 149(2):353-63. PMC: 1941956. DOI: 10.1111/j.1365-2249.2007.03422.x. View